ADIL - Adial Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5100
+0.1400 (+10.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.3700
Open1.4000
Bid1.4500 x 1800
Ask1.6000 x 1000
Day's Range1.3945 - 1.6600
52 Week Range1.3400 - 9.4400
Volume130,588
Avg. Volume41,269
Market Cap16M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • ACCESSWIRE

    Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 29, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed the final packaging of its lead investigational drug product, AD04 for the treatment of alcohol use disorder ("AUD"), for use in its planned Phase 3 trial of AD04 (the "Trial"). As previously announced, the Company has partnered with Catalent Pharma Solutions, a leading global provider of advanced delivery, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, to advance clinical activities related to AD04, including packaging and distribution.

  • ACCESSWIRE

    Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker

    The genetic biomarker is part of the genetic panel used to identify patients for inclusion in Adial's Phase 3 trial of AD04 for the treatment of AUD in genetically targeted patients. William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "This Notice of Allowance by the USPTO is another important milestone as we progress towards Adial's planned Phase 3 trial of AD04 and further solidifies the patent estate around AD04.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that Mark Howard Peikin, Esq., Chief Executive Officer of Bespoke Growth Partners (Bespoke), and a former General Partner of Aelius Healthcare Innovations Fund and partner within the corporate and securities group at the international law firm Brown Rudnick, was appointed as Chief Strategy Officer and Vice President of Corporate Communications. As Adial conducts its European Phase 3 clinical trial of AD04 for the treatment of Alcohol Use Disorder (AUD), which trial will study subjects for 24-weeks with 290 subjects projected to be enrolled in approximately 30 clinical sites in 7 European countries, Mr. Peikin will help oversee Adial's discussions with pharmaceutical companies, as well as strategic and institutional investors.

  • ACCESSWIRE

    Adial Files Clinical Trial Application to Commence Phase 3 Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 1, 2019 / Adial Pharmaceuticals, Inc. (ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted its Clinical Trial Application (CTA) to commence the Phase 3 clinical trial of the Company's lead drug candidate, AD04, (the "Phase 3 Trial" or the "Trial") for the treatment of alcohol use disorder (AUD) in genetically targeted patients with the Swedish Medical Products Agency. "The filing of our CTA marks another important milestone, as we continue to execute on our plan," stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals.

  • We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • ACCESSWIRE

    Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its clinical activities. The Company reported that it is on track to complete its Clinical Trial Application (CTA) filing to commence the Phase 3 clinical trial of the Company's lead drug candidate, AD04, (the "Phase 3 Trial" or the "Trial") for the treatment of alcohol use disorder (AUD) in genetically targeted patients, on or before September 30, 2019. The Phase 3 Trial is expected to enroll 290 subjects across approximately 30 selected clinical sites in Sweden, Finland, Estonia, Latvia, Poland, Bulgaria and Croatia.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its previously manufactured supply of clinical trial material (CTM), consisting of blister packaged tablets of AD04, was successfully retested. All criteria, including, without limitation, identity testing, content uniformity, assay, impurities, microbial limits, and other tests showed the clinical trial materials have passed review and are within the pre-specified acceptable limits for use in clinical trials. The CTM is intended to be used in the upcoming Phase 3 clinical trial of AD04 as a treatment for alcohol use disorder (AUD) in genetically targeted patients.

  • ACCESSWIRE

    Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that the European Medicines Agency (EMA) has validated the Pediatric Investigation Plan (PIP) waiver application for AD04, the Company’s lead investigational new drug product for the treatment of Alcohol Use Disorder (AUD). William Stilley, CEO of Adial Pharmaceuticals, stated, “We are pleased have our PIP waiver application validated by the European Medicines Agency, as it completes another important step in the process to advance AD04 and apply for marketing approval in Europe.

  • ACCESSWIRE

    Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell''

    CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2019 / Adial Pharmaceuticals, Inc. (ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its Chief Executive Officer, William Stilley, will appear live today as a guest on Cheddar with hosts Hope King and Brad Smith at approximately 4:40 pm ET. Mr. Stilley plans to discuss the alcohol and opioid abuse problem in America as well as the Company’s lead investigational new drug product, AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.

  • Do Directors Own Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares?
    Simply Wall St.

    Do Directors Own Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares?

    The big shareholder groups in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) have power over the company. Generally...

  • ACCESSWIRE

    Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its Chief Medical Officer, Bankole Johnson, M.D., D.Sc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI, presented the Company's lead investigational new drug product, AD04, for the treatment of alcohol use disorder (AUD), at the Scientific Federation 7th World Congress on Nursing & Healthcare in London, England.

  • ACCESSWIRE

    Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the further strengthening of its intellectual property (IP) portfolio, as it has received a Notification Prior to Acceptance from the Israeli Intellectual Property Office on its patent for AD04, which covers the use of AD04 to treat certain genotypes for alcohol use disorder. William Stilley, CEO of Adial Pharmaceuticals, stated, "We are delighted to be awarded this patent as we believe the demographics and expected prevalence of the target genotype in Israel may support rapid adoption upon regulatory approval.

  • ACCESSWIRE

    Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization

    ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, and Tedor Pharma, Inc., a full-service contract development and manufacturing organization (CDMO), today announced that they entered into a collaboration agreement to provide cGMP contract manufacturing services for AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). Adial is on track to commence its first Phase 3 trial of AD04 next quarter and plans to conduct that trial using its current inventory of drug product.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder

    ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has entered into a collaboration agreement with Eurofins Scientific ("Eurofins"), a global scientific leader in bioanalytical testing, to provide the genetic testing during Adial Pharmaceutical's planned Phase 3 clinical trial ("Phase 3 Trial" or the "Trial"). The Phase 3 Trial is designed to study AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.

  • ACCESSWIRE

    Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City

    CHARLOTTESVILLE, VA / ACCESSWIRE / April 30 , 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, ...

  • Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve...

  • ACCESSWIRE

    Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that its Chief Medical Officer, Bankole Johnson, MD, a recent recipient of the American Society of Addiction Medicine's highest honor, was featured on WPTV-TV, the NBC affiliate in West Palm Beach, Florida. Dr. Johnson discussed the fight against alcohol use disorder (AUD), opioid addiction and the addiction epidemic.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the appointment of Alex Lugovoy as Head of Strategy. Mr. Lugovoy will further develop and advance the Company's corporate partnerships, licensing and mergers and acquisitions strategy.

  • ACCESSWIRE

    Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that its Chief Medical Officer, Bankole Johnson, M.D., will be delivering the keynote lecture at the 50th Annual American Society of Addiction Medicine Conference on April 5th in Orlando, Florida. At the Conference, Dr. Johnson is also being recognized as ASAM's 2019 recipient of the R. Brinkley Smithers Distinguished Scientist Award.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI has purchased 73,100 shares of the Company's common stock in the open market over the March 28 and March 29 trading days as reported on a Form 4 that Dr. Johnson filed with the Securities and Exchange Commission. Adial Pharmaceuticals previously announced Dr. Johnson's appointment as Chief Medical Officer of the Company, and prior to becoming the Chief Medical Officer, he served as Chairman of the Board of the Company.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer

    NASDAQ: ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI has joined the Company as its Chief Medical Officer. In connection with this new position, Dr. Johnson will step down from the Board of Directors of Adial and from his position as Chairman, and will also leave his position as the Chair of the Department of Psychiatry at the University of Maryland to devote greater focus to his new duties with the Company.

  • ACCESSWIRE

    Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed a Registration Statement on Form S-1 on March 22, 2019, to update certain information in the Registration Statement on Form S-1 that was declared effective on July 26, 2018. The Company is also seeking to register 125,000 shares of common stock under the Registration Statement on Form S-1 filed on March 22, 2019, in order to fulfill a contractual obligation to a prior holder of the Company's warrants and notes. The newly filed registration statement on Form S-1 is subject to review by the SEC before becoming effective.

  • Benzinga

    Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner

    More than 15 million Americans suffer from alcohol use disorder, according to the CDC, but a new medication may offer a solution. This week, Adial CEO Bill Stilley discussed the prospects for AD04 in an interview with CBS San Francisco affiliate KPIX-TV.

  • GlobeNewswire

    Adial Pharmaceuticals Featured on CBS in San Francisco

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced that William Stilley, President and Chief Executive Officer, appeared on the CBS affiliate, KPIX-TV, “Bay Area Focus” morning show on Tuesday, February 26, 2019. Mr. Stilley discussed the Company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.

  • GlobeNewswire

    Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announces the closing of its previously announced underwritten public offering of 2,845,000 shares of its common stock and warrants to purchase up to 2,133,750 shares of the Company's common stock, which included 370,000 shares of common stock and warrants to purchase up to 277,500 shares of common stock issued upon the partial exercise of the underwriters’ option to purchase additional securities to cover over-allotments. Each share of common stock was sold together with a warrant to purchase 0.75 of one share of common stock at a combined price to the public of $3.25.The warrants are immediately exercisable at a price of $4.0625 per share of common stock (subject to adjustment) and will expire five years from the date of issuance Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $9.2 million.